Govt Job: Walk in interview for Pharmacist at PGIMER

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

Post : Pharmacist

Project Title : A PHASE 2/3, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE SAFETY AND IMMUNOGENICITY OF COVOVAX [SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS- CoV-2 rS) WITH MATRJX-M1 ™ ADJUVANT| IN INDIAN ADULTS AGED > 18 YEARS AND CHILDREN AGED 2 TO 17 YEARS

Qualification : Essential B.Pharma / Diploma in pharmacy from a recognized institution / board, should be a registered pharmacist under the pharmacy act 1948 – Minimum 1 year of experience in dispensing and /or storage and dispensing of drugs in a reputed hospital or institution or in a drug stores of a pharmaceutical concern / Clinical research experience.

Tenure : 3 months

Salary : 33,300/-

Date of Interview : 03rd  September,2021 (Friday)

Time of Interview : 03:00 pm

Selection Process :  An online interview will be conducted on 03ri1 September 2021 at 3:00 PM via zoom/Google meet. In view of C-19, no face to face Interview will be conducted.

How to apply : Interested candidate should email their applications along with their curriculum vitae (softcopy of resume) with supporting documents address to Dr, Madhu Gupta, Professor on email ID : covovax2021@gmail.com

Last date: before 05:00 PM dated 31/08/2021. No applications will be entertained after 05:00 PM on 31/08/2021

Related Posts

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise